- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00922532
Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure
Inhaled Nitric Oxide For The Treatment Of Hypoxic Respiratory Failure With Pulmonary Hypertension In Preterm Infants
This Phase 3, Double-blind, Randomized, Placebo controlled, multicenter study is to confirm the efficacy of inhaled nitric oxide for the management of hypoxic respiratory failure associated with pulmonary hypertension in preterm infants.
Study subjects will be administered either inhaled nitric oxide or placebo to determine if there is a change in oxygenation.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This trial will be a multi-center, double blind, placebo-controlled, randomized clinical trial. All mothers identified with prolonged rupture of membranes and/or oligohydramnios, and all inborn infants < 30 weeks gestational age (GA) at birth will be screened for enrollment. Infants who meet all inclusion and exclusion criteria within the first 48 hours after birth will be randomized to either inhaled NO starting at 20 ppm, or matched placebo, delivered by means of a blinded INOvent® delivery device. Randomization will be stratified by center and treatment will be assigned using an interactive voice or web-based response system (IVRS). All infants will receive up to 14 days of therapy, following a dose reduction schedule. The primary outcome measure will be change in oxygenation at 1 hour after start of therapy. In order to determine the effects of iNO therapy on survival and need for mechanical ventilation, cross-over will not be allowed.
This clinical trial will attempt to demonstrate if pre-term infants may benefit from treatment with nitric oxide for inhalation. A multi-center study is necessary to recruit an appropriate number of subjects, and to reflect the variability of standard practice across the different participating centers. All treatment assignments are blinded in order to minimize the risk of bias in treatment and data collection. In addition, a concurrent placebo group has been chosen as the most appropriate control group since there may be temporal, institutional and national variations in average outcomes. Methemoglobin levels will be measured locally and will collected in a blinded manner.
Studietype
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Preterm infants who:
- Are in-born at < 30 weeks gestational age
- Weigh 500-1250 grams
- Have hypoxic respiratory failure requiring mechanical ventilation with FiO2 > 0.8 to maintain SaO2 ≥ 85% in the first 48 hours after birth after use of exogenous surfactant
- Have minimal parenchymal lung disease by chest X ray
Exclusion Criteria:
Preterm infants who:
- Have ten minute Apgar score < 5
- Have life-threatening anomalies (cardiac, thoracic, chromosomal) or congenital diaphragmatic hernia with lung hypoplasia, or any child who will not receive complete intensive care
- Have bilateral Grade IV Intraventricular Hemorrhage (IVH)
- Are dependent on right to left shunting to maintain the systemic circulation
- Have received prior iNO therapy
- Have had treatment with investigational medications
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Inhalert nitrogenoksid
|
Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
Andre navn:
|
Placebo komparator: Nitrogen
Nitrogen Placebo
|
Nitrogen gas will be administered in the same manor as the experimental drug
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Arterial Blood Gases
Tidsramme: Day 1 through Day 6
|
Day 1 through Day 6
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Uønskede hendelser
Tidsramme: Studievarighet
|
Studievarighet
|
Methemoglobin levels
Tidsramme: Treatment Duration
|
Treatment Duration
|
Vital Signs
Tidsramme: Study Duration
|
Study Duration
|
cGMP Levels
Tidsramme: Day 1 through 14
|
Day 1 through 14
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Sykdommer i luftveiene
- Respirasjonsforstyrrelser
- Lungesykdommer
- Tegn og symptomer, luftveier
- Hypertensjon
- Respiratorisk insuffisiens
- Hypertensjon, lunge
- Hypoksi
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Vasodilaterende midler
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Beskyttende agenter
- Bronkodilatatorer
- Anti-astmatiske midler
- Luftveismidler
- Antioksidanter
- Free Radical Scavengers
- Endotel-avhengige avslappende faktorer
- Gassendere
- Nitrogenoksid
Andre studie-ID-numre
- IK-3001-HRF-301
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Inhaled Nitric Oxide
-
Sanotize Research and Development corp.The Emmes Company, LLC; Keyrus Life ScienceFullførtKoronavirusinfeksjonCanada